Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLANTIS: Lurbinectedin/Doxorubicin vs CAV or Topotecan in SCLC
NCT02566993Phase 3Completed
- Sponsor
- PharmaMar
- Start
- Aug 2016
- Primary completion
- Feb 2020
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 20
01
Overview
A Phase 3 trial of lurbinectedin in small cell lung cancer (SCLC), sponsored by PharmaMar. Started Aug 2016; status: completed.
02
Drugs
lurbinectedin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02566993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02566993.